Patent Assignment
Reel/Frame 075021/0929
Security Interest
Recorded: 2026-03-06
Pages: 54
Assignor
BEAM THERAPEUTICS INC.
Executed: 2026-02-24
Assignee
SIXTH STREET LENDING PARTNERS, AS ADMINISTRATIVE AGENT
2100 MCKINNEY AVENUE, DALLAS, TEXAS, 75201
Covered Properties
(253)
Methods of Suppressing Pathogenic Mutations Using Programmable Base Editor Systems
Application:
62/670,498 →
Methods of Suppressing Pathogenic Mutations Using Programmable Base Editor Systems
Application:
62/780,864 →
Methods of Substituting Pathogenic Amino Acids Using Programmable Base Editor Systems
Application:
62/670,521 →
Methods of Substituting Pathogenic Amino Acids Using Programmable Base Editor Systems
Application:
62/780,890 →
Methods of Suppressing Pathogenic Mutations Using Programmable Base Editor Systems
Application:
17/054,393 →
Publication:
US 2021/0371858
Methods of Editing Gene Rgulatory Regions Using Programmable Base Editor Systems
Application:
62/670,539 →
Methods of Editing Single Nucleotide Polymorphism Using Programmable Base Editor Systems
Application:
62/670,588 →
Methods of Editing Single Nucleotide Polymorphism Using Programmable Base Editor Systems
Application:
62/780,838 →
Methods of Editing Single Nucleotide Polymorphism Using Programmable Base Editor Systems
Application:
62/817,986 →
Methods of Substituting Pathogenic Amino Acids Using Programmable Base Editor Systems
Methods of Substituting Pathogenic Amino Acids Using Programmable Base Editor Systems
Application:
18/807,580 →
Publication:
US 2025/0108098
Methods of Editing Single Nucleotide Polymorphism Using Programmable Base Editor Systems
Application:
17/054,348 →
Publication:
US 2023/0159956
Multi-Effector Nucleobase Editors and Methods of Using Same to Modify a Nucleic Acid Target Sequence
Application:
62/714,550 →
Compositions and Methods for Delivering a Nucleobase Editing System
Application:
62/728,703 →
Compositions and Methods for Delivering a Nucleobase Editing System
Application:
62/779,404 →
Multi-Effector Nucleobase Editors and Methods of Using Same to Modify a Nucleic Acid Target Sequence
Application:
17/265,440 →
Publication:
US 2021/0277379
Compositions and Methods for Improving Base Editing
Application:
62/728,698 →
Modified Immune Cells Having Enhanced Anti-Neoplasia Activity and Immunosuppression Resistance
Application:
62/793,277 →
Modified Immune Cells Having Enhanced Anti-Neoplasia Activity and Immunosuppression Resistance
Application:
62/839,870 →
Nucleobase Editors Having Reduced Non-Target Deamination and Assays for Characterizing Nucleobase Editors
Application:
62/799,702 →
Compositions and Methods for Delivering a Nucleobase Editing System
Compositions and Methods for Improving Base Editing
Modified Immune Cells Having Enhanced Anti-Neoplasia Activity and Immunosuppression Resistance
Application:
17/423,428 →
Publication:
US 2022/0133790
Nucleobase Editors Having Reduced Non-Target Deamination and Assays for Characterizing Nucleobase Editors
Application:
62/852,228 →
Programmable Variant Base Editor Systems and Methods of Using Same to Edit Single Nucleotide Polymorphisms
Application:
62/852,224 →
Nucleobase Editors Having Reduced Off-Target Deamination and Methods of Using Same to Modify a Nucleobase Target Sequence
Application:
62/941,569 →
Nucleobase Editors Having Reduced Non-Target Deamination and Assays for Characterizing Nucleobase Editors
Nucleobase Editors Having Reduced Off-Target Deamination and Methods of Using Same to Modify a Nucleobase Target Sequence
Application:
17/427,422 →
Publication:
US 2022/0136012
Compositions and Methods for Treating Alpha-1 Antitrypsin Deficiency (A1AD)
Application:
62/805,238 →
Adenosine Deaminase Base Editors and Methods of Using Same to Modify a Nucleobase Target Sequence
Application:
62/805,271 →
Adenosine Deaminase Base Editors and Methods of Using Same to Modify a Nucleobase Target Sequence
Application:
62/931,722 →
Adenosine Deaminase Base Editors and Methods of Using Same to Modify a Nucleobase Target Sequence
Application:
62/966,526 →
Compositions and Methods for Treating Alpha-1 Antitrypsin Deficiency
Compositions and Methods for Treating Sickle Cell Disease
Application:
62/805,277 →
Compositions and Methods for Treating Sickle Cell Disease
Application:
62/931,747 →
Adenosine Deaminase Base Editors and Methods of Using Same to Modify a Nucleobase in a Target Sequence
Adenosine Deaminase Base Editors and Methods of Using Same to Modify a Nucleobase in a Target Sequence
Application:
17/430,669 →
Publication:
US 2022/0170027
Adenosine Deaminase Base Editors and Methods of Using Same to Modify a Nucleobase in a Target Sequence
Application:
18/486,913 →
Publication:
US 2024/0132867
Compositions and Methods for Treating Hemoglobinopathies
Cytidine Deaminase Nucleobase Editors Having Enhanced Target Specificity
Application:
62/835,456 →
Compositions and Methods for Treating Hepatitis B
Application:
62/846,422 →
Compositions and Methods for Treating Hepatitis B
Application:
62/927,585 →
Compositions and Methods for Treating Hemoglobinopathies
Compositions and Methods for Treating Hemoglobinopathies
Application:
17/430,298 →
Publication:
US 2022/0235347
Compositions and Methods for Treating Hemoglobinopathies
Compositions and Methods for Treating Hemoglobinopathies
Compositions and Methods for Treating Hemoglobinopathies
Application:
19/372,908 →
Publication:
US 2026/0108590
Compositions and Methods for Treating Hemoglobinopathies
Application:
19/389,788 →
Publication:
US 2026/0061041
Methods of Editing Single Nucleotide Polymorphism Using Programmable Base Editor Systems
Application:
62/850,919 →
Methods of Editing Single Nucleotide Polymorphism Using Programmable Adenosine Base Editor Systems
Application:
62/873,138 →
Splice Acceptor Site Disruption of a Disease-Associated Gene Using Programmable Base Editor Systems
Application:
62/873,140 →
Compositions and Methods for Treating Hepatitis B
Application:
17/610,119 →
Publication:
US 2023/0070861
Methods of Editing a Single Nucleotide Polymorphism Using Programmable Base Editor Systems
Application:
17/612,879 →
Publication:
US 2022/0387622
Methods of Editing Single Nucleotide Polymorphism Using Programmable Base Editor Systems
Application:
17/054,324 →
Publication:
US 2021/0380955
Methods of Editing a Disease-Associated Gene Using Adenosine Deaminase Base Editors, Including for the Treatment of Genetic Disease
Application:
17/430,672 →
Publication:
US 2023/0140953
Methods of Editing a Disease-Associated Gene Using Programmable Adenosine Base Editor Systems
Application:
62/873,144 →
Methods of Editing Single Nucleotide Polymorphism Using Programmable Adenosine Base Editor Systems
Application:
62/876,354 →
Methods of Editing Single Nucleotide Polymorphism Using Programmable Adenosine Base Editor Systems
Application:
62/912,992 →
Splice Acceptor Site Disruption of a Disease-Associated Gene Using Adenosine Deaminase Base Editors, Including for the Treatment of Genetic Disease
Application:
17/430,289 →
Publication:
US 2022/0098593
Compositions and Methods for Treating Glycogen Storage Disease Type 1A
Application:
17/430,274 →
Publication:
US 2022/0127594
Compositions and Methods for Non-Toxic Conditioning
Application:
62/893,677 →
Compositions and Methods for Editing a Mutation to Permit Transcription or Expression
Application:
62/893,638 →
Compositions and Methods for Treatment of Liquid Cancers
Application:
62/907,254 →
Novel Nucleobase Editors and Methods of Using Same
Application:
62/897,777 →
Compositions and Methods for Non-Toxic Conditioning
Application:
17/638,683 →
Publication:
US 2023/0017979
Compositions and Methods for Editing a Mutation to Permit Transcription or Expression
Application:
17/638,757 →
Publication:
US 2022/0313799
Compositions and Methods for Treatment of Liquid Cancers
Modified Immune Cells Having Adenosine Deaminase Base Editors and Methods of Using Same to Modify a Nucleobase Target Sequence
Application:
62/941,523 →
Compositions and Methods for Engraftment of Base Edited Cells
Application:
62/976,239 →
Compositions and Methods for Treating a Hemoglobinopathy
Application:
63/355,980 →
Novel Nucleobase Editors and Methods of Using Same
Application:
17/641,343 →
Publication:
US 2023/0075877
Modified Immune Cells Having Adenosine Deaminase Base Editors for Modifying a Nucleobase in a Target Sequence
Compositions and Methods for Engraftment of Base Edited Cells
Application:
17/799,159 →
Publication:
US 2023/0242884
Adenosine Deaminase Base Editors and Methods for Use Thereof
Application:
18/984,585 →
Publication:
US 2025/0144149
Fratricide Resistant Modified Immune Cells and Methods of Using the Same
Application:
63/083,540 →
Compositions and Methods for the Treatment of Hereditary Angioedema (Hae)
Application:
63/278,417 →
Systems and Methods for Implemented Mixed Reality in Laboratory Automation
Application:
62/801,045 →
Fratricide Resistant Modified Immune Cells and Methods of Using the Same
Compositions and Methods for the Treatment of Hereditary Angioedema (Hae)
Application:
18/661,004 →
Publication:
US 2024/0360433
Systems and Methods for Implemented Mixed Reality in Laboratory Automation
Modified Regulatory T Cells and Methods of Using the Same
Application:
63/348,753 →
Compositions and Methods for the Treatment of Spinal Muscular Atrophy (Sma)
Application:
63/291,290 →
Persistent Allogeneic Modified Immune Cells and Methods of Use Thereof
Application:
63/293,722 →
Persistent Allogeneic Modified Immune Cells and Methods of Use Thereof
Application:
63/336,109 →
Modified Regulatory T Cells and Methods of Using the Same
Application:
18/965,215 →
Publication:
US 2025/0090585
Compositions and Methods for the Treatment of Spinal Muscular Atrophy (Sma)
Application:
18/744,175 →
Publication:
US 2024/0335516
Persistent Allogeneic Modified Immune Cells and Methods of Use Thereof
Application:
18/441,740 →
Publication:
US 2024/0287453
Compositions and Methods for Non-Genotoxic Cell Conditioning
Application:
63/355,927 →
Compositions and Methods for Non-Genotoxic Cell Conditioning
Application:
63/386,719 →
Compositions and Methods for Non-Genotoxic Cell Conditioning
Application:
63/478,744 →
Compositions and Methods for Non-Genotoxic Cell Conditioning
Application:
63/500,854 →
Modified Allogeneic Cells and Methods and Compositions for the Preparation Thereof
Application:
63/373,644 →
Synthetic Polypeptides and Uses Thereof
Application:
63/377,131 →
Compositions and Methods for Non-Genotoxic Cell Conditioning
Application:
18/984,508 →
Publication:
US 2026/0166085
Modified Allogeneic Cells and Methods and Compositions for the Preparation Thereof
Application:
19/062,951 →
Publication:
US 2025/0186589
Synthetic Polypeptides and Uses Thereof
Application:
63/497,632 →
Base Editing of Transthyretin Gene
Application:
63/191,458 →
Base Editing of Transthyretin Gene
Application:
63/322,182 →
Base Editing of Transthyretin Gene
Application:
63/383,394 →
Compositions and Methods for Treating Glycogen Storage Disease Type 1A
Application:
63/091,891 →
Compositions and Methods for Treating Glycogen Storage Disease Type 1A
Application:
63/248,081 →
Synthetic Polypeptides and Uses Thereof
Application:
19/090,220 →
Publication:
US 2025/0223614
Base Editing of Transthyretin Gene
Application:
18/515,118 →
Publication:
US 2024/0124536
Base Editing of Transthyretin Gene
Application:
19/204,091 →
Publication:
US 2025/0312491
Compositions and Methods for Cell Conditioning
Application:
63/641,097 →
Adenosine Deaminase Variants and Uses Thereof
Application:
63/166,778 →
Adenosine Deaminase Variants and Uses Thereof
Application:
63/229,057 →
Compositions and Methods for the Self-Inactivation of Base Editors
Application:
63/194,431 →
Compositions and Methods for Treating Glycogen Storage Disease Type 1A
Application:
18/031,547 →
Publication:
US 2023/0383277
Adenosine Deaminase Variants and Uses Thereof
Application:
18/474,969 →
Publication:
US 2024/0158775
Compositions and Methods for Editing a Transthyretin Gene
Application:
63/385,004 →
Compositions and Methods for Treating Stargardt Disease
Application:
63/499,756 →
Compositions and Methods for Treating Stargardt Disease
Application:
63/585,456 →
Immunosuppressant-Resistant Modified Allogeneic Modified Immune Cells and Methods for Use Thereof
Application:
63/491,364 →
Immunosuppressant-Resistant Modified Allogeneic Modified Immune Cells and Methods for Use Thereof
Application:
63/621,953 →
Compositions and Methods for the Self-Inactivation of Base Editors
Application:
18/519,954 →
Publication:
US 2024/0132868
Compositions and Methods for Editing a Transthyretin Gene
Application:
19/209,589 →
Publication:
US 2025/0325702
Compositions and Methods for Treating Stargardt Disease
Application:
19/370,363 →
Publication:
US 2026/0062704
Immunosuppressant-Resistant Modified Allogeneic Modified Immune Cells and Methods for Use Thereof
Application:
63/563,135 →
Methods and Compositions for Treating Alpha-1 Antitrypsin Deficiency
Application:
63/508,469 →
Methods and Compositions for Treating Alpha-1 Antitrypsin Deficiency
Application:
63/580,925 →
Modified Immune Effector Cells with Improved Resistance to Natural Killer Cell-Mediated Allorejection
Application:
63/516,398 →
Modified Immune Effector Cells with Improved Resistance to Natural Killer Cell-Mediated Allorejection
Application:
63/597,888 →
Modified Immune Effector Cells with Improved Resistance to Natural Killer Cell-Mediated Allorejection
Application:
63/564,681 →
Modified Immune Cells and Methods of Using the Same
Application:
63/288,462 →
Modified Immune Cells and Methods of Using the Same
Application:
63/355,036 →
Modified Immune Cells and Methods of Using the Same
Application:
63/378,607 →
Methods and Compositions for Anti-CD45 Based Non-Genotoxic Conditioning
Application:
63/502,335 →
Modified Immune Cells and Methods of Using the Same
Application:
18/737,787 →
Publication:
US 2024/0325533
Methods and Compositions for Anti-CD45 Based Non-Genotoxic Conditioning
Application:
19/388,302 →
Publication:
US 2026/0130997
Compositions and Methods for Treating Hepatitis B
Application:
63/248,938 →
Compositions and Methods for Treating Hepatitis B
Application:
63/357,623 →
Compositions and Methods for Treating Hepatitis B Virus Infection
Application:
63/371,634 →
Compositions and Methods for Treating Transthyretin Amyloidosis
Application:
63/189,060 →
Compositions and Methods for Reducing Complement Activation
Application:
63/352,547 →
Compositions and Methods for Treating Hepatitis B Virus Infection
Application:
18/617,539 →
Publication:
US 2024/0294914
Compositions and Methods for Treating Transthyretin Amyloidosis
Application:
18/507,980 →
Publication:
US 2024/0117345
Compositions and Methods for Reducing Complement Activation
Application:
18/979,227 →
Publication:
US 2025/0108132
Compositions and Methods for Treating a Congenital Eye Disease
Application:
63/369,881 →
Modified Immune Effector Cells with Improved Efficacy
Application:
63/495,682 →
Anti-Idiotypic Antibodies to Cluster of Differentiation 7-Targeted Binding Domains and Related Compositions and Methods
Application:
63/511,135 →
CD5-Binding Polypeptides, Compositions Comprising the Same, and Methods for Use Thereof
Application:
63/520,065 →
CD5-Binding Polypeptides, Compositions Comprising the Same, and Methods for Use Thereof
Application:
63/592,339 →
Compositions and Methods for Treating a Congenital Eye Disease
Application:
19/034,326 →
Publication:
US 2025/0223587
Modified Immune Effector Cells with Improved Efficacy
Application:
19/354,669 →
Publication:
US 2026/0117176
Compositions and Methods for Altering Complement Activation
Application:
63/601,145 →
Compositions and Methods for Base Editing a Phenylalanine Hydroxylase Polynucleotide
Application:
63/582,942 →
Compositions and Methods for Altering a Nucleobase in a Lipoprotein(a) Polynucleotide
Application:
63/583,795 →
Compositions and Methods for Altering a Nucleobase in a Transthyretin Polynucleotide
Application:
63/624,030 →
CD19-Binding Polypeptides, Compositions Comprising the Same, and Methods for Use Thereof
Application:
63/612,146 →
Base Editors with Modified Editing Windows
Application:
63/613,554 →
Modified Immune Cells with Increased Resistance to Allorejection
Application:
63/618,520 →
Modified Immune Cells with Increased Resistance to Allorejection
Application:
63/682,578 →
Modified Immune Cells with Increased Resistance to Allorejection
Application:
63/726,729 →
Methods and Compositions for Editing a Phenylalanine Hydroxylase Polynucleotide
Application:
63/690,276 →
Methods and Compositions for Editing a Gene Associated with Phenylketonuria (Pku)
Application:
63/719,298 →
Hemoglobin G-Makassar Binding Polypeptides and Antibodies and Methods of Using Same
Application:
63/329,109 →
Hemoglobin G-Makassar Binding Polypeptides and Antibodies and Methods of Using the Same
Application:
18/908,540 →
Publication:
US 2025/0102524
Novel Crispr Enzymes, Methods, Systems and Uses Thereof
Application:
62/897,929 →
Novel Crispr Enzymes, Methods, Systems and Uses Thereof
Application:
62/907,238 →
Novel Crispr Enzymes, Methods, Systems and Uses Thereof
Application:
17/641,356 →
Publication:
US 2023/0279373
Synthetic Guide Rna, Compositions, Methods, and Uses Thereof
Application:
63/031,262 →
Novel Crispr Enzymes, Methods, Systems and Uses Thereof
Application:
63/164,798 →
Genetic Modification of Hepatocytes
Application:
63/176,104 →
Synthetic Guide Rna, Compositions, Methods, and Uses Thereof
Application:
17/782,045 →
Publication:
US 2023/0055682
Novel Crispr Enzymes, Methods, Systems and Uses Thereof
Application:
18/283,148 →
Publication:
US 2024/0167008
Genetic Modification of Hepatocytes
Application:
18/486,067 →
Publication:
US 2024/0252550
Circular Guide Rnas for Crispr/Cas Editing Systems
Application:
18/526,492 →
Publication:
US 2024/0376468
Circular Guide Rnas for Crispr/Cas Editing Systems
Application:
63/196,039 →
Circular Guide Rnas for Crispr/Cas Editing Systems
Application:
63/305,128 →
Guide Rnas for Crispr/Cas Editing Systems
Application:
63/225,322 →
Crispr Enzymes, Methods, Systems and Uses Thereof
Application:
63/291,252 →
Guide Rnas for Crispr/Cas Editing Systems
Application:
18/418,751 →
Publication:
US 2024/0301405
Crispr Enzymes, Methods, Systems and Uses Thereof
Application:
18/736,840 →
Publication:
US 2024/0327813
Novel Rna Base Editing Compositions, Systems, Methods and Uses Thereof
Application:
18/904,904 →
Publication:
US 2025/0025573
Rna Base Editing Compositions, Systems, Methods and Uses Thereof
Application:
19/093,872 →
Publication:
US 2025/0288690
Novel Rna Base Editing Compositions, Systems, Methods and Uses Thereof
Application:
63/327,140 →
Large Serine Recombinases, Systems and Uses Thereof
Application:
63/407,487 →
One Vector System for Identification of Genome Modifying Enzymes
Application:
63/407,494 →
Modified Guide Rna
Application:
63/462,873 →
Stable Rna Compositions with Stem Loop, and Methods Thereof
Application:
63/561,046 →
Large Serine Recombinases, Systems and Uses Thereof
Application:
19/079,568 →
Publication:
US 2025/0236852
One Vector System for Identification of Genome Modifying Enzymes
Application:
19/079,571 →
Publication:
US 2025/0215423
Pseudotyped Recombinant Lyssaviruses for Gene Therapy
Application:
63/225,898 →
Recombinant Rabies Viruses for Gene Therapy
Application:
63/151,542 →
Recombinant Rabies Viruses for Gene Therapy
Application:
63/241,989 →
Viral Guide Rna Delivery
Application:
63/241,964 →
Pseudotyped Recombinant Lyssaviruses for Gene Therapy
Application:
17/873,666 →
Publication:
US 2023/0110201
Recombinant Rabies Viruses for Gene Therapy
Application:
17/651,738 →
Publication:
US 2022/0290164
Viral Guide Rna Delivery
Application:
17/940,636 →
Publication:
US 2023/0270840
Chimeric Pseudotyped Recombinant Rabies Virus
Application:
63/442,714 →
Prime Editing of Single Base Mutations in Sickle Cell Disease
Application:
63/533,011 →
Interferon Inhibition with Viral Proteins and Fragments and Fusions Thereof
Application:
63/532,808 →
Prime Editing of Single Base Mutations in Alpha-1 Antitrypsin Deficiency
Application:
63/565,839 →
Identification of Nanoparticles for Preferential Tissue or Cell Targeting
Application:
63/346,808 →
Chimeric Pseudotyped Recombinant Rabies Virus
Application:
18/428,690 →
Publication:
US 2024/0327802
Prime Editing of Single Base Mutations in Alpha-1 Antitrypsin Deficiency
Application:
19/080,343 →
Publication:
US 2025/0354138
Nanomaterials
Application:
63/128,685 →
Nanomaterials
Application:
63/128,680 →
Nanomaterials
Application:
63/223,971 →
Nanomaterials
Application:
63/287,390 →
Nanomaterials
Application:
63/128,682 →
Nanomaterials
Application:
63/139,730 →
Nanomaterials Comprising Carbonates
Application:
18/211,840 →
Publication:
US 2023/0357133
Nanomaterials Comprising Ester-Linked Acetals
Application:
18/211,857 →
Publication:
US 2023/0331657
Nanomaterials Comprising Acetals
Application:
18/211,822 →
Publication:
US 2023/0331656
Nanomaterials
Application:
63/139,731 →
Nanomaterials
Application:
63/139,732 →
Nanomaterials
Application:
63/139,734 →
Ionizable Lipids for Nanomaterials
Application:
18/220,874 →
Publication:
US 2023/0348359
Nanomaterials Comprising a Biodegradable Feature
Nanomaterials Comprising a Biodegradable Feature
Application:
19/058,752 →
Publication:
US 2025/0387509
Nanomaterials Comprising an Ionizable Lipid
Application:
18/220,867 →
Publication:
US 2024/0115511
Nanomaterials
Nanomaterials
Application:
18/751,931 →
Publication:
US 2025/0041441
Nanomaterials Comprising Diamines
Application:
63/291,574 →
Nanomaterials Comprising Diamines
Application:
63/354,631 →
Nanomaterials Comprising Disulfides
Application:
63/291,586 →
Nanomaterials Comprising Disulfides
Application:
63/354,636 →
Nanomaterials Comprising Tetravalent Lipid Compounds
Application:
63/291,593 →
Nanomaterials Comprising Diamines
Application:
18/746,766 →
Publication:
US 2024/0335541
Nanomaterials Comprising Disulfides
Application:
18/746,787 →
Publication:
US 2024/0335542
Nanomaterials Comprising Tetravalent Lipid Compounds
Application:
63/354,640 →
Nanomaterials Comprising Aryl Rings
Application:
63/291,613 →
Nanomaterials Comprising Aryl Rings
Application:
63/354,639 →
Nanomaterials Comprising Tetravalent Lipid Compounds
Application:
18/746,791 →
Publication:
US 2024/0358841
Ionizable Amine and Ester Lipids and Lipid Nanoparticles
Application:
18/746,797 →
Publication:
US 2024/0335543
Nanomaterials Comprising Trivalent Lipid Compounds
Application:
63/291,639 →
Nanomaterials Comprising Trivalent Lipid Compounds
Application:
63/354,627 →
Ionizable Amine Lipids and Lipid Nanoparticles
Application:
18/746,810 →
Publication:
US 2024/0335385
Uses of Adenosine Base Editors
Application:
62/573,127 →
Uses of Adenosine Base Editors
Uses of Adenosine Base Editors
Application:
18/460,178 →
Publication:
US 2024/0124866
Identification of Nanoparticles for Preferential Tissue or Cell Targeting
Application:
18/960,564 →
Publication:
US 2025/0092450
Nanomaterials Comprising Triols
Application:
63/390,882 →
Nanomaterials Comprising Triols
Nanomaterials Comprising Triols
Application:
19/083,032 →
Publication:
US 2025/0213493
Ionizable Lipids with Branched Head Groups
Application:
63/520,073 →
Ionizable Lipids with Branched Head Groups
Application:
63/520,305 →
Ionizable Lipids with Linear Head Groups
Application:
63/520,075 →
Ionizable Lipids with Linear Head Groups
Application:
63/520,310 →
Secondary Alcohol Lipids
Application:
63/712,808 →
Analysis of Materials for Tissue Delivery
Application:
62/857,676 →
Nanomaterials
Application:
62/944,735 →
Nanomaterials
Application:
62/958,876 →
Analysis of Materials for Tissue Delivery
Application:
17/596,187 →
Publication:
US 2022/0233459
Nanomaterials
Application:
17/110,070 →
Publication:
US 2021/0169804
Nanomaterials
Application:
18/673,962 →
Publication:
US 2025/0000797
Nanomaterials
Nanomaterials
Application:
19/317,946 →
Publication:
US 2026/0001838
Dna-Dependent Dna Polymerase Compositions, Methods, and Uses Thereof
Application:
63/584,641 →
Dna Ligase Compositions, Methods, and Uses Thereof
Application:
63/584,712 →
Synthetic Guide Rna, Compositions, Methods, and Uses Thereof
Application:
62/943,158 →
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Jun 8, 2018
From: EVANS, JOHN; PACKER, MICHAEL
To: BEAM THERAPEUTICS, INC.
Reel/Frame 046030/0841 →
Assignment of Assignor's Interest
Jun 8, 2018
From: EVANS, JOHN; FU, YANFANG; PACKER, MICHAEL
To: BEAM THERAPEUTICS, INC.
Reel/Frame 046030/0812 →
Assignment of Assignor's Interest
Jun 11, 2018
From: BRYSON, DAVID; EVANS, JOHN; PACKER, MICHAEL
To: BEAM THERAPEUTICS, INC.
Reel/Frame 046332/0512 →
Assignment of Assignor's Interest
Jun 11, 2018
From: BRYSON, DAVID; FU, YANFANG; PACKER, MICHAEL
To: BEAM THERAPEUTICS, INC.
Reel/Frame 046040/0933 →
Assignment of Assignor's Interest
Aug 24, 2018
From: GAUDELLI, NICOLE; EVANS, JOHN
To: BEAM THERAPEUTICS INC.
Reel/Frame 046700/0455 →
Assignment of Assignor's Interest
Sep 18, 2018
From: EVANS, JOHN
To: BEAM THERAPEUTICS INC.
Reel/Frame 046894/0810 →
Assignment of Assignor's Interest
Sep 18, 2018
From: BRYSON, DAVID
To: BEAM THERAPEUTICS INC.
Reel/Frame 046894/0769 →
Assignment of Assignor's Interest
Oct 19, 2018
From: GEHRKE, JASON MICHAEL
To: BEAM THERAPEUTICS INC.
Reel/Frame 047233/0963 →
Assignment of Assignor's Interest
Dec 27, 2018
From: BRYSON, DAVID
To: BEAM THERAPEUTICS INC.
Reel/Frame 047857/0945 →
Assignment of Assignor's Interest
Dec 27, 2018
From: PACKER, MICHAEL
To: BEAM THERAPEUTICS INC.
Reel/Frame 047857/0889 →
Assignment of Assignor's Interest
Dec 27, 2018
From: PACKER, MICHAEL
To: BEAM THERAPEUTICS INC.
Reel/Frame 047857/0854 →
Assignment of Assignor's Interest
Jan 29, 2019
From: GEHRKE, JASON MICHAEL; EDWARDS, AARON D.
To: BEAM THERAPEUTICS INC.
Reel/Frame 048164/0573 →
Assignment of Assignor's Interest
Apr 30, 2019
From: PACKER, MICHAEL; GAUDELLI, NICOLE
To: BEAM THERAPEUTICS INC.
Reel/Frame 049030/0537 →
Assignment of Assignor's Interest
May 7, 2019
From: JOUNG, J. KEITH; FU, YANFANG; GAUDELLI, NICOLE; PACKER, MICHAEL
To: BEAM THERAPEUTICS INC.
Reel/Frame 049097/0814 →
Assignment of Assignor's Interest
May 24, 2019
From: GAUDELLI, NICOLE; PACKER, MICHAEL
To: BEAM THERAPEUTICS INC.
Reel/Frame 049277/0280 →
Assignment of Assignor's Interest
May 24, 2019
From: GAUDELLI, NICOLE; PACKER, MICHAEL
To: BEAM THERAPEUTICS INC.
Reel/Frame 049277/0199 →
Assignment of Assignor's Interest
May 24, 2019
From: GEHRKE, JASON MICHAEL; PETROSSIAN, NATALIE; PACKER, MICHAEL
To: BEAM THERAPEUTICS INC.
Reel/Frame 049277/0390 →
Assignment of Assignor's Interest
Jul 2, 2019
From: GEHRKE, JASON MICHAEL; EDWARDS, AARON D.; MURRAY, RYAN
To: BEAM THERAPEUTICS INC.
Reel/Frame 049655/0593 →
Assignment of Assignor's Interest
Jul 10, 2019
From: SLAYMAKER, IAN; GAUDELLI, NICOLE; YU, YI
To: BEAM THERAPEUTICS INC.
Reel/Frame 049719/0861 →
Assignment of Assignor's Interest
Jul 18, 2019
From: ZETSCHE, BERND; SLAYMAKER, IAN
To: BEAM THERAPEUTICS INC.
Reel/Frame 049792/0792 →
Assignment of Assignor's Interest
Aug 15, 2019
From: SLAYMAKER, IAN; GEHRKE, JASON MICHAEL; GAUDELLI, NICOLE; YU, YI
To: BEAM THERAPEUTICS INC.
Reel/Frame 050059/0391 →
Assignment of Assignor's Interest
Nov 13, 2019
From: GAUDELLI, NICOLE; PACKER, MICHAEL
To: BEAM THERAPEUTICS INC.
Reel/Frame 050998/0849 →
Assignment of Assignor's Interest
Jan 2, 2020
From: YU, YI; BORN, DAVID A.; LEE, SEUNG-JOO
To: BEAM THERAPEUTICS INC.
Reel/Frame 051400/0481 →
Assignment of Assignor's Interest
Feb 5, 2020
From: GAUDELLI, NICOLE; PACKER, MICHAEL
To: BEAM THERAPEUTICS INC.
Reel/Frame 051724/0826 →
Assignment of Assignor's Interest
Nov 25, 2020
From: EVANS, JOHN; FU, YANGFANG; PACKER, MICHAEL
To: BEAM THERAPEUTICS INC.
Reel/Frame 054465/0216 →